Related Experiment Video
Updated: Mar 3, 2026
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
Reducing Recurrence of C. difficile Infection
Michael G Dieterle1, Vincent B Young1
1University of Michigan Medical School, Ann Arbor, MI 48103, USA.
Antibiotic use can cause recurrent Clostridium difficile infection (CDI). Bezlotoxumab, a monoclonal antibody, targets C. difficile toxin B, potentially reducing CDI recurrence by protecting the gut lining and aiding microbiome restoration.
Area of Science:
- Microbiology
- Immunology
- Gastroenterology
Background:
- Clostridium difficile infection (CDI) frequently recurs after initial treatment, impacting patient health.
- Antibiotic administration disrupts the gut microbiome, creating an environment conducive to CDI.
- Current antimicrobial therapies for CDI have a significant recurrence rate of approximately 20%.
Purpose of the Study:
- To evaluate the efficacy of bezlotoxumab in preventing CDI recurrence.
- To investigate the mechanism by which bezlotoxumab may reduce CDI recurrence.
Main Methods:
- Bezlotoxumab, a human monoclonal antibody, was administered to patients with CDI.
- The antibody targets Clostridium difficile toxin B (TcdB).
Main Results:
- Bezlotoxumab treatment was associated with reduced CDI recurrence in patients.
- The antibody's mechanism is presumed to involve limiting epithelial damage caused by TcdB.
- Facilitation of microbiome recovery is another potential benefit.
Conclusions:
- Bezlotoxumab shows promise as a therapeutic option to prevent recurrent CDI.
- Targeting C. difficile toxin B represents a viable strategy for managing recurrent infections.
- Further research may elucidate the full impact on epithelial integrity and microbiome dynamics.
More Related Videos
12:58A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
09:12A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
Published on: June 15, 2018
Related Concept Videos
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:26Stages of Infection
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:17Transmission-based Precautions I: Contact, Enteric, and Droplets
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...